ORG Wealth Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

ORG Wealth Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$45	Buy	+3	New	+$72	﹤0.01%	2507

Other funds holding RARE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

ORG Wealth Partners's RARE Position: Q3 2026 in Review

ORG Wealth Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q3 2026: 3 shares worth $45. The stake represents ﹤0.01% of the portfolio and ranks #2507 among its holdings.

110 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

ORG Wealth Partners held 3 shares of Ultragenyx Pharmaceutical worth $45 as of Q3 2026.
Ultragenyx Pharmaceutical was a new ORG Wealth Partners position in Q3 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of ORG Wealth Partners's portfolio in Q3 2026, its #2507 holding.
110 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on ORG Wealth Partners's 13F filing for Q3 2026, filed 3 Nov 2026.